<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02479321</url>
  </required_header>
  <id_info>
    <org_study_id>CEIC 15/03</org_study_id>
    <nct_id>NCT02479321</nct_id>
  </id_info>
  <brief_title>Perioperative Goal Directed Hemodynamic Therapy Based on Noninvasive Monitoring in Patients With Hip Fracture</brief_title>
  <official_title>Efficacy of Perioperative Goal Directed Hemodynamic Therapy Based on Noninvasive Monitoring to Reduce Perioperative Complications in Patients With Hip Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Althaia Xarxa Assistencial Universitària de Manresa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Althaia Xarxa Assistencial Universitària de Manresa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crude incidence rate in Spain of hip fracture in people over 65 years was 511 cases per
      100,000 in 2002. About 30% of patients die in the first year. Cardiocirculatory complications
      during and after surgery partly explain this high morbidity and mortality. Most patients are
      frail and with multicomorbidity. Perioperative Goal-Directed Hemodynamic Therapy (PGDT) based
      on noninvasive continuous monitoring of blood pressure, heart rate, oxygen saturation,
      cardiac output, cardiac index, stroke volume and stroke volume index can reduce perioperative
      complications and improve survival. The objective of our study is to assess the efficacy of a
      goal-directed hemodynamic therapy during the perioperative period in reducing intraoperative
      complications, especially hemodynamic instability, postoperative complications and 1-year
      survival. Patients and Methods: non-randomized intervention study with a historical control
      and 1-year follow-up. Patients older than 64 years with non-traumatic hip fracture requiring
      surgical intervention. In the control group blood pressure, heart rate, oxygen saturation and
      clinical situation besides respiratory parameters were recorded at intervals of 15 minutes.
      In the intervention group PGDT based on noninvasive monitoring will be performed. The main
      outcome will be the percentage of patients with hemodynamic instability complications and the
      average of complications per patient. Secondary outcomes: intraoperative complications,
      postoperative complications and survival at 12 months of surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative hemodynamic instability</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>A value of systolic blood pressure less than 90 mmHg and/or the need for a bolus of vasoconstrictor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative complications</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>Cardiocirculatory, respiratory, neurological, renal, infectious and major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected median of 11 days</time_frame>
    <description>Cardiocirculatory, respiratory, neurological, renal, infectious and major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected median of 11 days</time_frame>
    <description>Length of hospital stay (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>One-year survival</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">568</enrollment>
  <condition>Hip Fractures</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Hemodynamic optimization according to the standards of perioperative monitoring of our center. In the intraoperative and immediate postoperative period hemodynamic monitoring will be done by controlling blood pressure, heart rate, oxygen saturation and diuresis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PGDT noninvasive monitoring group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGDT based on noninvasive monitoring System ClearSight® and Platform EV Clinic 1000®</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PGDT based on noninvasive monitoring</intervention_name>
    <description>Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based PGDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.
In the intra and postoperative period (4 hours), hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. In case of instability a Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders.</description>
    <arm_group_label>PGDT noninvasive monitoring group</arm_group_label>
    <other_name>Perioperative Goal-Directed Hemodynamic Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>System ClearSight® and Platform EV Clinic 1000®</intervention_name>
    <description>Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index. We will also collect hourly diuresis and blood loss.</description>
    <arm_group_label>PGDT noninvasive monitoring group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hip fracture that require surgical treatment

          -  Agree to participate and sign informed consent

        Exclusion Criteria:

          -  Pathological fracture

          -  High-impact trauma fracture

          -  Anesthetic contraindication for surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Bosch Sabater, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Althaia Xarxa Assistencial Universitària de Manresa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesca Reguant Corominas, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Althaia Xarxa Assistencial Universitària de Manresa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan Víctor Lorente Olazábal, MD</last_name>
    <phone>938742112</phone>
    <email>jlorente@althaia.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Arnau Bartés, MSc</last_name>
    <phone>93 875 93 00</phone>
    <phone_ext>3414</phone_ext>
    <email>aarnau@althaia.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Althaia Xarxa Assistencial Universitària de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Víctor Lorente Olazábal, MD</last_name>
      <phone>+34938742121</phone>
      <email>jlorente@althaia.cat</email>
    </contact>
    <contact_backup>
      <last_name>Anna Arnau Bartés, MSc</last_name>
      <phone>+34938759300</phone>
      <phone_ext>3414</phone_ext>
      <email>aarnau@althaia.cat</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2015</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Althaia Xarxa Assistencial Universitària de Manresa</investigator_affiliation>
    <investigator_full_name>Juan Víctor</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Perioperative Goal-Directed Hemodynamic Therapy</keyword>
  <keyword>Fluid therapy</keyword>
  <keyword>Aged</keyword>
  <keyword>Perioperative complications</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

